- Rein Therapeutics (RNTX, Financial) secures two new U.S. patents for LTI-03.
- The drug targets multiple respiratory conditions using a dual mechanism.
- Phase 2 clinical trials for LTI-03 in idiopathic pulmonary fibrosis (IPF) set to commence in the first half of 2025.
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company specializing in innovative therapies for pulmonary and fibrosis conditions, has announced the acquisition of two new U.S. patents. These patents, numbered 12,280,088 and 12,280,089, were issued on April 22, 2025, by the U.S. Patent and Trademark Office (USPTO). They cover the dry powder formulation and therapeutic use of LTI-03, a novel synthetic peptide designed for the treatment of various respiratory diseases.
The drug LTI-03 is known for its dual mechanism of action, targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, a strategy potentially beneficial for conditions such as interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory or fibrotic lung conditions. The formulation is administered via dry powder inhalation.
The patents solidify Rein Therapeutics' intellectual property portfolio and provide strong support as the company advances LTI-03 toward clinical application. Rein Therapeutics plans to initiate Phase 2 clinical trials focused on IPF in the first half of 2025, testing the drug's efficacy in addressing significant unmet medical needs.
